StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Oculis Holding AG (OCS)

Thu, 11 Jun 2026 06:43:41 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $26.00 price target on Oculis Holding AG (NASDAQ: OCS).

The analyst commented: "Yesterday, Oculis announced that the first patient had been randomized in the registrational Phase 2b/3 PREDICT-1 trial of licaminlimab (or OCS-02) for the treatment of dry eye disease (DED). The study is designed to evaluate the efficacy of licaminlimab in DED symptoms and its safety compared with vehicle in patients carrying a specific TNFR1 genotype. According to the protocol, PREDICT-1 is a randomized, multi-center, double-masked, vehicle-controlled study that is slated to enroll approximately 160 patients, and approximately 2/3 of

Oculis Holding AG (OCS) PT Lowered to $23 at JPMorgan

Wed, 03 Jun 2026 08:37:45 -0400

JPMorgan analyst Tessa Romero lowered the price target on Oculis Holding AG (NASDAQ: OCS) to $23.00 (from $42.00) while maintaining a Overweight rating.

Oculis Holding AG (OCS) PT Lowered to $38 at Baird

Tue, 02 Jun 2026 06:16:30 -0400

Baird analyst Collen Kusy lowered the price target on Oculis Holding AG (NASDAQ: OCS) to $38.00 (from $49.00) while maintaining a Outperform rating.

Oculis Holding AG (OCS) PT Lowered to $40 at Stifel After Disappointing Ph3 Results

Mon, 01 Jun 2026 07:26:10 -0400

Stifel analyst Annabel Samimy lowered the price target on Oculis Holding AG (NASDAQ: OCS) to $40.00 (from $50.00) while maintaining a Buy rating.

The analyst commented, "Following the disappointing Ph.3 DIAMOND-1/2 results, OCS has halted further development for OCS-01 in DME. This effectively clears the way to prioritize neuroprotective agent privosegtor—supported by the successful Ph.2 PoC ACUITY trial that uniquely showed improvement on both structural AND functional endpoints of AON. These results subsequently drove FDA Breakthrough and EMA PRIME designations, acceleration into pivotal trials for multiple ophthalmic indications (AONdata 2027), and expansion into MS. Meanwhile, the Ph.3 PIONEER-1 trial of licaminlimab

Oculis Holding AG (OCS) PT Lowered to $40 at Stifel After Disappointing Ph3 Results

Mon, 01 Jun 2026 07:26:10 -0400

Stifel analyst Annabel Samimy lowered the price target on Oculis Holding AG (NASDAQ: OCS) to $40.00 (from $50.00) while maintaining a Buy rating.

Oculis Holding AG (OCS) PT Lowered to $45 at Guggenheim

Mon, 01 Jun 2026 07:17:03 -0400

Guggenheim analyst Yatin Suneja lowered the price target on Oculis Holding AG (NASDAQ: OCS) to $45.00 (from $75.00) while maintaining a Buy rating.

Oculis Holding AG (OCS) PT Lowered to $38 at Needham

Mon, 01 Jun 2026 07:06:13 -0400

(Updated - June 1, 2026 7:06 AM EDT)

Needham analyst Serge Belanger lowered the price target on Oculis Holding AG (NASDAQ: OCS) to $38.00 (from $46.00) while maintaining a Buy rating.

The analyst commented: The two ph 3 trials (DIAMOND-1 and-2) evaluating OCS-01 as a topical DME treatment missed their 52wk primary endpoint based on visual acuity gains. OCS is discontinuing the program to focus on privosegtor (OCS-05) development in optic neuropathies, and licaminlimab (OCS-02) clinical trials in dry eye disease (DED).

OCS investor focus has largely shifted towards privosegtor as the co's main value driver over the last ~18mths. While the ph

Oculis Holding AG (OCS) PT Lowered to $38 at Needham

Mon, 01 Jun 2026 07:06:13 -0400

(Updated - June 1, 2026 7:06 AM EDT)

Needham analyst Serge Belanger lowered the price target on Oculis Holding AG (NASDAQ: OCS) to $38.00 (from $46.00) while maintaining a Buy rating.

OCS investor focus has largely shifted towards privosegtor as the co's main value driver over the last ~18mths. While the ph

Oculis Holding AG (OCS) PT Lowered to $26 at H.C. Wainwright

Mon, 01 Jun 2026 06:55:05 -0400

(Updated - June 1, 2026 6:55 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on Oculis Holding AG (NASDAQ: OCS) to $26.00 (from $47.00) while maintaining a Buy rating.

The analyst commented: "Last Friday, Oculis reported topline results from the two Phase 3 DIAMOND trials of OCS-01 eye drops (topical OPTIREACH formulation of dexamethasone) for the treatment of diabetic macular edema (DME). The two trials enrolled over 800 DME patients, who were randomized 1:1 to receive OCS-01 or vehicle six times daily for a six-week induction phase and then three times daily for a subsequent 46-week maintenance phase (for

Oculis Holding AG (OCS) PT Lowered to $26 at H.C. Wainwright

Mon, 01 Jun 2026 06:55:05 -0400

(Updated - June 1, 2026 6:55 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on Oculis Holding AG (NASDAQ: OCS) to $26.00 (from $47.00) while maintaining a Buy rating.

Form 6-K Oculis Holding AG For: May 29

Mon, 01 Jun 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260601/26578237.html

Form 6-K Oculis Holding AG For: May 29

Mon, 01 Jun 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260601/26578237.html

Oculis fails to meet primary endpoint in diabetic macular edema trials

Fri, 29 May 2026 15:06:06 -0400

Oculis Holding AG (NASDAQ: OCS) announced that its Phase 3 DIAMOND trials of OCS-01 eye drops for diabetic macular edema did not meet the primary endpoint of improved visual acuity after 52 weeks of treatment.

The DIAMOND-1 and DIAMOND-2 trials enrolled over 800 patients at 119 sites across the United States and other countries. The primary endpoint measured mean change in best corrected visual acuity from baseline to week 52. Both trials failed to demonstrate significant improvement in this measure.

The trials did show a secondary endpoint of substantial and persistent reduction in retinal thickness with OCS-01 compared to placebo in DIAMOND-2

Oculis fails to meet primary endpoint in diabetic macular edema trials

Fri, 29 May 2026 15:06:06 -0400

The trials did show a secondary endpoint of substantial and persistent reduction in retinal thickness with OCS-01 compared to placebo in DIAMOND-2

Oculis fails to meet primary endpoint in diabetic macular edema trials

Fri, 29 May 2026 15:06:06 -0400

The trials did show a secondary endpoint of substantial and persistent reduction in retinal thickness with OCS-01 compared to placebo in DIAMOND-2

Oculis fails to meet primary endpoint in diabetic macular edema trials

Fri, 29 May 2026 15:06:06 -0400

The trials did show a secondary endpoint of substantial and persistent reduction in retinal thickness with OCS-01 compared to placebo in DIAMOND-2

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

Fri, 29 May 2026 15:05:00 -0400

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met
The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials
Oculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye disease
Financial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

Fri, 29 May 2026 15:05:00 -0400

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met

The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials

Oculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye disease

Financial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

Fri, 29 May 2026 15:05:00 -0400

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met

The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials

Oculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye disease

Financial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

Fri, 29 May 2026 15:05:00 -0400

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met

The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials

Oculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye disease

Financial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

Fri, 29 May 2026 15:05:00 -0400

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met

The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials

Oculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye disease

Financial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

Fri, 29 May 2026 15:05:00 -0400

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met

The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials

Oculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye disease

Financial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

Fri, 29 May 2026 15:05:00 -0400

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met

The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials

Oculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye disease

Financial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

Fri, 29 May 2026 15:05:00 -0400

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met

The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials

Oculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye disease

Financial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash

Oculis OCS-01 eye drops fail primary endpoints in diabetic macular edema trials

Fri, 29 May 2026 14:54:09 -0400

Oculis Holding AG (NASDAQ: OCS) announced that its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops did not meet their primary endpoint in patients with diabetic macular edema.
The primary endpoint of mean change in best corrected visual acuity from baseline to week 52 was not met in both trials, which enrolled over 800 patients across 119 investigational sites in the United States and other countries. The key secondary endpoint measuring the proportion of patients with at least 15-letter gain in visual acuity also was not achieved in either trial.
The secondary endpoint of retinal thickness showed a reduction with